ERBB2 and non-small cell lung carcinoma: Recently, two more studies reported data on 13 and 21 HER2-mutated NSCLC patients, respectively, showing that 3/13 had a PD-L1 expression > 50% [79] and 4/21 tumors a PD-L1 expression > 1% [78].